Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Briquilimab's Promise | Explore Jasper Therapeutics' lead candidate briquilimab, showing potential in chronic urticaria treatment with promising early trial results and differentiated dosing schedule |
Financial Tightrope | Delve into Jasper's precarious financial position, with a cash runway through 2025 and the need for additional capital amid recent setbacks and market challenges |
Market Opportunity | Learn about the substantial chronic urticaria market, with over 3 million U.S. patients and limited FDA-approved options, presenting a significant opportunity for Jaspe |
Analyst Optimism | Discover why analysts maintain positive outlooks despite challenges, with price targets ranging from $12 to $70, highlighting briquilimab's potential in a competitive landscape |
Metrics to compare | JSPR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJSPRPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.5x | −2.9x | −0.5x | |
PEG Ratio | 0.02 | 0.03 | 0.00 | |
Price/Book | 2.0x | 2.5x | 2.6x | |
Price / LTM Sales | - | 8.3x | 3.3x | |
Upside (Analyst Target) | - | 216.8% | 38.7% | |
Fair Value Upside | Unlock | 2.5% | 5.0% | Unlock |